Daugherty A - Search Results

1

Development of poly-(D,L-lactide--coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis.

Cleland JL, Duenas ET, Park A, Daugherty A, Kahn J, Kowalski J, Cuthbertson A. Cleland JL, et al. Among authors: daugherty a. J Control Release. 2001 May 14;72(1-3):13-24. doi: 10.1016/s0168-3659(01)00258-9. J Control Release. 2001. PMID: 11389981

2

Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes.

Lam XM, Duenas ET, Daugherty AL, Levin N, Cleland JL. Lam XM, et al. Among authors: daugherty al. J Control Release. 2000 Jul 3;67(2-3):281-92. doi: 10.1016/s0168-3659(00)00224-8. J Control Release. 2000. PMID: 10825561

3

Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response.

Cleland JL, Lim A, Daugherty A, Barron L, Desjardin N, Duenas ET, Eastman DJ, Vennari JC, Wrin T, Berman P, Murthy KK, Powell MF. Cleland JL, et al. Among authors: daugherty a. J Pharm Sci. 1998 Dec;87(12):1489-95. doi: 10.1021/js980263f. J Pharm Sci. 1998. PMID: 10189254

4

Emerging protein delivery methods.

Cleland JL, Daugherty A, Mrsny R. Cleland JL, et al. Among authors: daugherty a. Curr Opin Biotechnol. 2001 Apr;12(2):212-9. doi: 10.1016/s0958-1669(00)00202-0. Curr Opin Biotechnol. 2001. PMID: 11287240 Review.

5

Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response.

Cleland JL, Barrón L, Berman PW, Daugherty A, Gregory T, Lim A, Vennari J, Wrin T, Powell MF. Cleland JL, et al. Among authors: daugherty a. J Pharm Sci. 1996 Dec;85(12):1346-9. doi: 10.1021/js960047b. J Pharm Sci. 1996. PMID: 8961151

6

Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120.

Cleland JL, Barrón L, Daugherty A, Eastman D, Kensil C, Lim A, Weissburg RP, Wrin T, Vennari J, Powell MF. Cleland JL, et al. Among authors: daugherty a. J Pharm Sci. 1996 Dec;85(12):1350-7. doi: 10.1021/js960329b. J Pharm Sci. 1996. PMID: 8961152

7

Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover.

Street J, Bao M, deGuzman L, Bunting S, Peale FV Jr, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A, van Bruggen N, Redmond HP, Carano RA, Filvaroff EH. Street J, et al. Among authors: daugherty a. Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9656-61. doi: 10.1073/pnas.152324099. Epub 2002 Jul 12. Proc Natl Acad Sci U S A. 2002. PMID: 12118119 Free PMC article.

8

Sustained release formulations of rhVEGF₁₆₅ produce a durable response in a murine model of peripheral angiogenesis.

Daugherty AL, Rangell LK, Eckert R, Zavala-Solorio J, Peale F, Mrsny RJ. Daugherty AL, et al. Eur J Pharm Biopharm. 2011 Jun;78(2):289-97. doi: 10.1016/j.ejpb.2011.03.011. Epub 2011 Mar 21. Eur J Pharm Biopharm. 2011. PMID: 21426936

9

Local tissue distribution and cellular fate of vascular endothelial growth factor (VEGF) following intramuscular injection.

Daugherty AL, Mrsny RJ. Daugherty AL, et al. J Drug Target. 2010 Jan;18(1):27-35. doi: 10.3109/10611860903134317. J Drug Target. 2010. PMID: 19624285

10

Epithelial application of Pseudomonas aeruginosa exotoxin A results in a selective targeting to cells in the liver, spleen and lymph node.

Daugherty AL, McKee ML, FitzGerald DJ, Mrsny RJ. Daugherty AL, et al. J Control Release. 2000 Mar 1;65(1-2):297-302. doi: 10.1016/s0168-3659(99)00251-5. J Control Release. 2000. PMID: 10699289

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

551 results

Search Page

Filters